Back to Report Store Home

Global Cancer Vaccines Market to 2022 – Robust Growth Driven by Increasing Prevalence, New Therapeutic Vaccine Approvals and Strong Uptake of Treatments Targeting CD19

  • Published: Nov-2016
  • Report Code: GBIHC424MR
  • Report Format: pdf

Description

List of Figures

Figure 1: Cancer Vaccines Market, Major Markets, Treatment Usage Patterns for Cervical Cancer, Patients (‘000), 2015–2022 17

Figure 2: Cancer Vaccines Market, Major Markets, Treatment Usage Patterns for Liver Cancer, Patients (‘000), 2015–2022 18

Figure 3: Cancer Vaccines Market, Major Markets, Treatment Usage Patterns for Melanoma, Patients (‘000), 2015–2022 19

Figure 4: Cancer Vaccines Market, Major Markets, Treatment Usage Patterns for Prostate Cancer, Patients (‘000), 2015–2022 20

Figure 5: Cancer Vaccines Market, Global, Key Marketed Products and Approved Indications, 2016 31

Figure 6: Cancer Vaccines Market, Global, Annual Revenues for Gardasil ($bn), 2006–2022 33

Figure 7: Cancer Vaccines Market, Global, Annual Revenues for Provenge ($m), 2010–2022 34

Figure 8: Cancer Vaccines Market, Global, Annual Revenues for Cervarix ($m), 2007–2022 36

Figure 9: Cancer Vaccines Market, Global, Annual Revenues for Imlygic ($m), 2015–2022 37

Figure 10: Cancer Vaccines Market, Global, Overall Pharmaceutical Industry Pipeline by Therapy Area, 2016 41

Figure 11: Cancer Vaccines Market, Global, Pipeline for Therapeutic Cancer Vaccines by Stage of Development and Molecule Type, 2016 42

Figure 12: Cancer Vaccines Market, Global, Pipeline for Prophylactic Cancer Vaccines by Stage of Development and Molecule Type, 2016 43

Figure 13: Cancer Vaccines Market, Global, Pipeline for Key Oncology Indications by Stage of Development, 2016 44

Figure 14: Cancer Vaccines Market, Global, Pipeline for Key Oncology Indications by Molecule Type, 2016 45

Figure 15: Cancer Vaccines Market, Global, Pipeline for Therapeutic Vaccines by Indication and Molecular Target, 2016 46

Figure 16: Cancer Vaccines Market, Global, Pipeline for Prophylactic Vaccines by Indication and Molecular Target, 2016 47

Figure 17: Cancer Vaccines Market, Global, Pipeline for Key Oncology Indications by Molecular Target, 2016 48

Figure 18: Cancer Vaccines Market, Global, Clinical Trial Failure Rates by Stage of Development and Overall Clinical Trial Attrition Rate (%), 2006–2016 49

Figure 19: Cancer Vaccines Market, Global, Clinical Trial Failure Rates by Stage of Development and Indication (%), 2006–2016 50

Figure 20: Cancer Vaccines Market, Global, Clinical Trial Failure Rates by Stage of Development and Molecule Type (%), 2006–2016 51

Figure 21: Cancer Vaccines Market, Global, Clinical Trial Failure Rates by Stage of Development and Molecular Target (%), 2006–2016 52

Figure 22: Cancer Vaccines Market, Global, Clinical Trial Duration by Stage of Development (months), 2006–2016 53

Figure 23: Cancer Vaccines Market, Global, Clinical Trial Duration by Stage of Development and Indication (months), 2006–2016 54

Figure 24: Cancer Vaccines Market, Global, Clinical Trial Duration by Stage of Development and Molecule Type (months), 2006–2016 55

Figure 25: Cancer Vaccines Market, Global, Clinical Trial Duration by Stage of Development and Molecular Target (months), 2006–2016 56

Figure 26: Cancer Vaccines Market, Global, Clinical Trial Size by Stage of Development (participants), 2006–2016 57

Figure 27: Cancer Vaccines Market, Global, Clinical Trial Size by Stage of Development and Indication (participants), 2006–2016 57

Figure 28: Cancer Vaccines Market, Global, Clinical Trial Size by Stage of Development and Molecule Type (participants), 2006–2016 58

Figure 29: Cancer Vaccines Market, Global, Clinical Trial Size by Stage of Development and Molecular Target (participants), 2006–2016 59

Figure 30: Cancer Vaccines Market, Global, Clinical Program Size by Stage of Development (participants), 2006–2016 60

Figure 31: Cancer Vaccines Market, Global, Clinical Program Size by Stage of Development and Indication (participants), 2006–2016 61

Figure 32: Cancer Vaccines Market, Global, Clinical Program Size by Stage of Development and Molecule Type (participants), 2006–2016 62

Figure 33: Cancer Vaccines Market, Global, Clinical Program Size by Stage of Development and Molecular Target (participants), 2006–2016 63

Figure 34: Cancer Vaccines Market , Global, Revenue Forecast for Tisagenlecleucel-T ($bn), 2017–2022 65

Figure 35: Cancer Vaccines Market, Global, Revenue Forecast for KTE-C19 ($bn), 2017–2022 66

Figure 36: Cancer Vaccines Market, Global, Revenue Forecast for JCAR-017 ($bn), 2017–2022 67

Figure 37: Cancer Vaccines Market, Global, Revenue Forecast for JCAR-015 ($m), 2018–2022 68

Figure 38: Cancer Vaccines Market, Global, Revenue Forecast for bb-2121 ($m), 2019–2022 69

Figure 39: Cancer Vaccines Market, Global, Revenue Forecast for Prostvac ($m), 2016–2022 70

Figure 40: Cancer Vaccines Market, Global, Revenue Forecast for Cellular Immunotherapy to Target HPV-16 E6 Protein for Cancer ($m), 2018–2022 71

Figure 41: Cancer Vaccines Market, Global, Market Size ($bn), 2015–2022 74

Figure 42: Cancer Vaccines Market, Global, Market Size ($bn) 75

Figure 42: Cancer Vaccines Market, Global, Annual Revenue Forecast for Prophylactic and Therapeutic Products ($bn), 2015–2022 76

Figure 43: Cancer Vaccines Market, Global, Annual Revenue Forecast for HPV L1 Major Capsid Protein ($bn), 2015–2022 78

Figure 44: Cancer Vaccines Market, Global, Annual Revenue Forecast for Hepatitis B Surface Antigen ($m), 2015–2022 79

Figure 45: Cancer Vaccines Market, Global, Annual Revenue Forecast for Cluster of Differentiation 19 ($bn), 2017–2022 80

Figure 46: Cancer Vaccines Market, Global, Annual Revenue Forecast for Granulocyte Macrophage Colony Stimulating Factor ($m), 2016–2022 81

Figure 47: Cancer Vaccines Market, Global, Annual Revenue Forecast for Tumor Necrosis Factor Receptor Superfamily Member 17 ($m), 2019–2022 81

Figure 48: Cancer Vaccines Market, Global, Annual Revenue Forecast for Prostatic Acid Phosphatase ($m), 2015–2022 82

Figure 49: Cancer Vaccines Market, Global, Companies by Type, Cluster by Growth and Market Share, 2015–2022 83

Figure 50: Cancer Vaccines Market, Global, Company Analysis Matrix, 2016 84

Figure 51: Cancer Vaccine Market, Global, Forecast Market Share by Company (%), 2015–2022 86

Figure 52: Cancer Vaccines Market, Global, Companies by Compound Annual Growth Rate (%), 2015–2022 87

Figure 53: Cancer Vaccines Market, Global, Revenues by Product Type, 2015–2022 88

Figure 54: Cancer Vaccines Market, Global, Merck & Co Annual Revenue Forecast ($bn), 2015–2022 89

Figure 55: Cancer Vaccines Market, Global, GSK Annual Revenue Forecast ($m), 2015–2022 90

Figure 56: Cancer Vaccines Market, Global, Novartis Annual Revenue Forecast ($bn), 2017–2022 91

Figure 57: Cancer Vaccines Market, Global, Kite Pharma Annual Revenue Forecast ($bn), 2017–2022 92

Figure 58: Cancer Vaccines Market, Amgen Annual Revenue Forecast ($m), 2016–2022 93

Figure 59: Cancer Vaccines Market, Juno Therapeutics Annual Revenue Forecast ($bn), 2017–2022 94

Figure 60: Cancer Vaccines Market, Global, Valeant Annual Revenue Forecast ($m), 2015–2022 94

Figure 61: Cancer Vaccines Market, Global, Bluebird Bio Annual Revenue Forecast ($m), 2019–2022 95

Figure 62: Cancer Vaccines Market, Global, Bavarian Nordic Annual Revenue Forecast ($m), 2016–2022 96

Figure 60: Cancer Vaccines Market, Global, Companies by Type, 2015–2022 97

Figure 61: Cancer Vaccines Market, Global, Pipeline, High-Activity and Late-Stage Developers by Level of Cancer Vaccine Specialization, 2015–2022 98

Figure 62: Cancer Vaccines Market, Global, Proportion of Total Company Revenue Attributed to Cancer Vaccines, 2015–2022 99

Figure 64: Cancer Vaccines Market, Global, Licensing Deals by Region and Value, 2006–2016 101

Figure 65: Cancer Vaccines Market, Global, Licensing Deals by Indication and Value, 2006–2016 102

Figure 68: Cancer Vaccines Market, Global, Licensing Deals by Stage of Development and Value, 2006–2016 103

Figure 67: Cancer Vaccines Market, Global, Licensing Deals by Molecule Type and Molecular Target, 2006–2016 104

Figure 68: Cancer Vaccines Market, Global, Co-development Deals by Region and Value, 2006–2016 109

Figure 69: Cancer Vaccines Market, Global, Co-development Deals by Indication and Value, 2006–2016 110

Figure 72: Cancer Vaccines Market, Global, Co-development Deals by Stage of Development and Value, 2006–2016 111

Figure 71: Cancer Vaccines Market, Global, Co-development Deals by Molecule Type and Mechanism of Action, 2006–2016 112

License Details
Electronic PDF copy delivered via email. Report can be used by individual purchaser only.
Single User Licence
$4995
Electronic PDF copy delivered via email. Report can be shared by unlimited users within one corporate location, e.g. a regional office.
Site Licence
$9990
Electronic PDF copy delivered via email. Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company.
Global Licence
$14985
Email to a colleague Enquire Before Buying
Prefer to speak to a team member? Call us on:
+44 161 359 5414
Or click here to contact us
Secure Payments
Cards